The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback